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Abstract
Background: The expression of a neural crest stem cell marker, polysialic acid (polySia), and its
main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors
with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of
polySia-NCAM in neuroblastoma is unclear.
Methods: A tumor tissue microarray (TMA) of 36 paraffin-embedded neuroblastoma samples was
utilized to detect polySia-NCAM expression with a polySia-binding fluorescent fusion protein, and
polySia-NCAM expression was compared with clinical stage, age, MYCN amplification status,
histology (INPC), and proliferation index (PI).
Results: PolySia-NCAM-positive neuroblastoma patients had more often metastases at diagnosis,
and polySia-NCAM expression associated with advanced disease (P = 0.047). Most interestingly,
absence of polySia-NCAM-expressing tumor cells in TMA samples, however, was a strong
unfavorable prognostic factor for overall survival in advanced disease (P = 0.0004), especially when
MYCN was not amplified. PolySia-NCAM-expressing bone marrow metastases were easily detected
in smears, aspirates and biopsies.
Conclusion: PolySia-NCAM appears to be a new clinically significant molecular marker in
neuroblastoma, hopefully with additional value in neuroblastoma risk stratification.
Background
Neuroblastoma is a highly malignant and metastatic
childhood cancer, which originates from the neural crest.
Bone marrow is the most common metastatic site of neu-
roblastomas; up to 60% of children have bone marrow
involvement at presentation [1]. Especially children older
than one year at diagnosis have metastatic disease, and the
overall 5-year event-free survival of stage 4 patients is only
16% [2]. In general, patients classified as high-risk for dis-
ease relapse have overall survival rates less than 40%
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nostic and therapeutic risk stratification is based primarily
on age (dichotomized around 18 months), stage, and
MYCN-amplification status.
Neural cell adhesion molecule (NCAM) is a cell surface
molecule, which is expressed in the nervous system and in
various cell types, such as natural killer cells (NK cells),
cardiomyocytes, and neuroendocrine cells. NCAM expres-
sion has also been detected in many malignancies, e.g. in
neuroblastoma, rhabdomyosarcoma, non-small cell lung
carcinoma (NSCLC), small cell lung cancer (SCLC), brain
tumors, myelomas and acute myeloid leukemia [3-9].
Although NCAM expression is not solely restricted to
malignant cells, high-level expression of NCAM in a vari-
ety of malignancies makes an anti-NCAM approach attrac-
tive for cancer therapy. In vivo and in vitro experiments
with huN901-DM1, a humanized variant of the murine
monoclonal anti-NCAM antibody [10], support the idea
of utilizing therapeutic anti-NCAM antibodies [8,11].
Currently, huN901-DM1-based anti-NCAM treatments of
small cell lung cancer, NCAM-positive solid tumors and
multiple myeloma are in phase I/II clinical studies http://
www.immunogen.com/wt/page/IMGN901b.
Polysialic acid (polySia) is a linear α-2–8-linked sialic acid
polymer, which is covalently attached to the NCAM mol-
ecule. PolySia is abundantly expressed in neural tissue
during embryonic development, but progressively down-
regulated during maturation and differentiation [12,13].
Although polySia is virtually absent in the majority of
adult tissues, it is reexpressed during the progression of
some metastasis-prone malignant tumors, such as neu-
roblastoma, rhabdomyosarcoma, NSCLC and SCLC [14-
18]. In these tumors, polysialylation appears to increase
the metastatic behavior [16,18-20]. Moreover, it has been
reported that polySia increases the motility of SCLC cells,
and allows the cancer cells to detach from the primary
tumor, thus causing the formation of metastatic foci [21].
In vitro, a significant reduction in neuroblastoma cell pro-
liferation has been demonstrated after removal of polySia
from the cell surface [22,23].
We conducted the search for polySia-NCAM and NCAM
by utilizing a tumor tissue microarray (TMA) of the 36
paraffin-embedded neuroblastoma samples, as described
earlier [24]. The expression of the oncodevelopmental
antigen polySia and its main carrier NCAM was compared
with the age, stage, MYCN-amplification status, histology
according to the International Neuroblastoma Pathology
Classification (INPC) [25] and proliferation index (PI).
Methods
Human tissue and tumor classifications
The study material consisted of a total of 37 paraffin-
embedded neuroblastoma samples from 37 patients,
which have been described in more detail previously
[24,26]. Because of sample detachment, the expression
pattern of polySia and NCAM could not be analyzed in
one TMA sample. Therefore, the overall number of TMA
samples was 36, of which 31 were primary neuroblastoma
samples taken before any treatments. For histological typ-
ing and grading, the INPC system was applied [25]. The
clinical stage of 22 cases could not be evaluated according
to the International Neuroblastoma Staging System
(INSS) [27], because these tumors were diagnosed before
1993, when protocols evaluating dissemination status
were heterogeneous. Therefore, dissemination status was
evaluated on the basis of medical records, and the clinical
stage of the disease was divided into four categories: 1)
local tumor, extirpation (completely excised); 2) local
tumor with regional lymph node involvement; 3) distant
metastases; 4) tumors that met INSS Stage 4S definition
[27].
A total of 19 paraffin-embedded bone marrow samples
(range 1–7 samples per patient; median two samples per
patient) from six patients was available. The original his-
topathological analysis of the samples revealed two cer-
tain and one uncertain bone marrow involvements. These
three samples had been taken from the same patient
(diagnosed in 2001) at different time points. The primary
tumor was undifferentiated neuroblastoma (stage 4) with
unfavorable histology (INPC).
Immunostaining of molecular markers and detection of 
MYCN amplification in TMAs
TMAs of neuroblastomas were constructed as described
earlier [24]. Tumor TMA slides, bone marrow core biopsy
samples on slides, and bone marrow aspiration smears
were used for conventional immunostainings. Prolifera-
tion indices (PIs) with anti-Ki-67 antibody were detected
as described earlier [24]. PolySia-binding fluorescent
fusion protein (EndoNA2-GFP) at a concentration of 10
μg/ml was used for polySia detection as described earlier
[28]. Mouse anti-human NCAM antibody (123C3) at a
concentration of 4 μg/ml (Santa Cruz Biotechnology,
Santa Cruz, CA) was used as a primary antibody. Immu-
nohistochemical incubations were done overnight at 4°C.
In immunofluorescence, Alexa Fluor 594 chicken anti-
mouse secondary antibodies (Molecular Probes, Eugene,
OR) were used, and slides were mounted with Immu-
Mount (Shandon, USA). The MYCN copy number in
tumor TMAs of neuroblastomas was quantified by CISH
analysis with a digoxigenin-labeled probe complementary
to the MYCN gene (Spot-Light N-Myc Probe, Zymed,
South San Francisco, CA) as previously described [24].
Bone marrow smears and flow cytometry
Bone marrow samples were prepared from an aspirate,
obtained from an 18-year-old man, whose bone marrow
was examined for nonmalignant anemia. For bone mar-Page 2 of 8
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cultured human neuroblastoma SH-SY5Y cells (0, 50 and
100%), and the EndoNA2-GFP fusion protein [28] at a
concentration of 10 μg/ml was used for staining the
smears. For flow cytometry, bone marrow cells (100 μl,
3.5 × 106) and polySia-NCAM-positive SH-SY5Y cells
(100 μl, 3.5 × 106) were labeled with the EndoNA2-GFP
(10 μg/ml) fusion protein [28] for 20 minutes at room
temperature. Red cells were lysed with FACS lysis buffer
(Becton-Dickinson, NJ, USA). The cell suspensions were
analyzed with a FACSCalibur flow cytometer (Becton-
Dickinson).
Confocal microscopy
We performed confocal scanning microscopy for the TMA
of the 36 paraffin-embedded neuroblastoma samples
using a Leica TCS SP MP confocal microscope equipped
with a Spectra-Physics Tsunami Ti-sapphire laser and
Leica confocal software. Sections were examined at two
excitation wavelengths: 488 nm for polySia-binding
fusion protein and 546 nm for fluorescent secondary anti-
bodies.
Statistical analyses
Differences between two groups in the categorical data
were analyzed by means of the Pearson chi-square test.
Overall survival analysis was computed using the Kaplan-
Meier method, and the differences between the curves
were compared using the log-rank test. Differences in
mean values between multiple groups were analyzed
using one-way Anova. All statistical analyses were per-
formed with SPSS 16.0 for Macintosh, and P values of <
0.05 were considered statistically significant.
Results
PolySia and NCAM expression in paraffin-embedded 
neuroblastoma samples
PolySia expression proved to be positive in 17 (54%) out
of 31 patients, whose neuroblastoma samples were taken
from primary tumors before any treatments (i.e. no treat-
ment effect on antigen expression). An example of the
staining pattern of polySia-NCAM is given in Figure 1.
PolySia-specific immunofluorescence was confirmed with
pretreatment of neuroblastoma samples with endosiali-
dase, which abolished polySia-positive immunofluores-
cent signals. All three metastatic neuroblastoma samples
from three patients were polySia- and NCAM-positive.
The unselected and overall proportion of patients with
polySia-positive neuroblastomas was 21 (58%) out of 36.
In our analysis series, there were no polySia-expressing
tumors, which did not show concomitant and colocalized
NCAM expression. NCAM is the carrier of cell surface
polySia: colocalization of polySia-NCAM and NCAM is
shown in Figure 1.
NCAM expression was positive in 20 (65%) out of 31 pri-
mary neuroblastoma samples, which were taken before
any treatments. The NCAM staining pattern is shown in
Figure 1. A negative NCAM staining control was obtained
by omission of the primary antibody. Three out of 20
NCAM-positive primary neuroblastomas did not express
polySia-NCAM. The unselected and overall proportion of
patients with NCAM-positive tumors was 24 (67%) out of
36.
The bone marrow disease was previously evaluated in 14
out of 31 patients with untreated primary neuroblasto-
The staining pattern of a primary neuroblastomaFigure 1
The staining pattern of a primary neuroblastoma. A, expression of polySia-NCAM detected with the EndoNA2-GFP 
fusion protein. B, NCAM expression (stained with Alexa Fluor 594) of the same location. C, overlay image of A and B identifying 
colocalized expression of polySia-NCAM and NCAM. Scale bar, 40 μm.Page 3 of 8
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the basis of medical records) to have bone marrow metas-
tases at diagnosis. PolySia-NCAM and NCAM expression
in untreated primary tumor samples (not metastatic sam-
ples from regional lymph nodes or distant organs) was
positive in 9 out of 11 patients with bone marrow disease.
One out of three patients without bone marrow involve-
ment had a polySia-NCAM- and NCAM-positive primary
neuroblastoma.
Association of polySia-NCAM and NCAM expression with 
clinical parameters (age and stage)
Patients' age did not associate with polySia-NCAM or
NCAM expression, not even when groups were dichot-
omized at age of 12 and 18 months (Table 1). PolySia-
NCAM expression in neuroblastomas did associate with
clinical stage, as patients with polySia-NCAM-expressing
primary tumors had advanced (i.e. metastatic) disease at
diagnosis (P = 0.047) (Table 1). The association between
NCAM expression and clinical stage was nearly significant
(P = 0.053) (Table 1).
Association of polySia-NCAM and NCAM expression with 
histological parameters (INPC, proliferation index [PI] and 
MYCN amplification)
Analysis of the correlation between polySia-NCAM
expression and tumor differentiation (INPC) revealed
that polySia-NCAM and NCAM were expressed more fre-
quently in undifferentiated and in poorly differentiating
than in differentiated neuroblastomas, but the P-value did
not reach significance (P = 0.623 for polySia-NCAM, and
P = 0.165 for NCAM) (Table 2). PolySia-NCAM- and
NCAM-expressing primary tumors showed higher PIs
than polySia-NCAM- and NCAM-negative tumors (P =
0.011 for polySia-NCAM, and P = 0.001 for NCAM)
(Table 2). There was no association between polySia-
NCAM or NCAM expression and MYCN amplification sta-
tus (Table 2). All patients with MYCN-amplified neurob-
lastomas (seven patients) had stage 4 disease (i.e. distant
metastases) at diagnosis.
Survival analyses
Negative polySia-NCAM expression was a strong unfavo-
rable predictor of overall survival in advanced disease, as
all seven patients with negative polySia-NCAM expression
and regional lymph node involvement or distant metas-
tases died during the follow-up time (Fig. 2) (P = 0.0004).
Negative NCAM expression was also an unfavorable pre-
dictor of outcome (P = 0.0088) in the same advanced dis-
ease group (Fig. 2). When the prognostic value of polySia-
NCAM and NCAM were evaluated solely for the 19
patients with distant metastases, they still reached signifi-
cant P-values (P = 0.0019 and P = 0.0240, respectively). In
comparison to the prognostic value of MYCN amplifica-
tion (not significant, P = 0.0666), polySia-NCAM and
NCAM were stronger predictors of unfavorable outcome
in patients with advanced disease (Fig. 2). The overall
prognostic significance of MYCN amplification in the
hotspot analysis has been presented previously [24].
Detection of polySia-NCAM-positive neuroblastic cells in 
bone marrow with immunofluorescence and flow 
cytometry
To investigate whether metastatic neuroblastoma cells in
bone marrow express polySia-NCAM, like their polySia-
NCAM positive primary tumor foci, 19 paraffin-embed-
ded bone marrow biopsies from six different patients were
labeled with the fluorescent fusion protein. PolySia-
NCAM-positive tumor cell clusters, as shown in Figure 3,
were found in two different bone marrow samples, taken
at different time points from the same patient with a poly-
Sia-NCAM positive primary tumor. Contrary to the pri-
mary tumors, polySia-NCAM positive bone marrow
neuroblastoma cells appeared to be in a non-proliferative
state, when samples were double-labeled with anti-Ki-67
antibody (Fig. 3).
Table 1: Association of polySia-NCAM and NCAM expression of untreated primary neuroblastomas with clinical variables.
Variable PolySia-NCAM-positive (17) PolySia-NCAM-negative (14) P value NCAM positive (20) NCAM negative (11) P value
MEAN AGE (31) 2.9 ± 3.3 4.6 ± 5.0 0.258 3.4 ± 3.9 4.1 ± 4.7 0.683
AGE (31) 0.613 0.890
< 1.0 year (8) 5 3 5 3
> 1.0 year (23) 12 11 15 8
0.465 0.939
< 1.5 yrs (11) 7 4 7 4
> 1.5 yrs (20) 10 10 13 7
CLINICAL STAGE (31) 0.047 0.053
LD, extirpation (7) 1 6 2 5
LD with RLNI (4) 3 1 3 1
Distant metastases (19) 13 6 15 4
INSS 4S (1) 0 1 1
Number of patients in each variable group is shown in parenthesis. P-values are measured for differences between categorical variables (polySia-NCAM or NCAM 
expression status). Abbreviations: LD = local disease; RLNI = regional lymph node involvement; BM = bone marrow; INSS = International Neuroblastoma Staging 
SystemPage 4 of 8
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NCAM-positive SH-SY5Y neuroblastic cells were mixed
together in different ratios, and the mixed cell suspen-
sions were labeled with the polySia-binding fluorescent
fusion protein. Interestingly, smears with added polySia-
NCAM-positive SH-SY5Y cells appeared in cell clusters,
like in fixed bone marrow biopsy samples, whereas
smears without added SH-SY5Y cells did not show any cell
clustering. Normal bone marrow samples were consid-
ered polySia-NCAM-negative, even though they con-
tained a few single cells (approximately 1–3 individual
cells per microscopic field), which were polySia-NCAM-
positive, but significantly smaller in size than polySia-
NCAM-positive tumor cell clusters.
In evaluating the possible applicability of flow cytometry
to differentiate bone marrow metastases (polySia-NCAM-
positive neuroblastoma cells or cell clusters) from normal
bone marrow cells, our results revealed that polySia-
NCAM-positive tumor cells produce distinct fluorescence
when compared to fusion protein-labeled normal bone
marrow cells (Fig. 4). As we had no permission to take
fresh bone marrow samples from neuroblastoma patients
for research purposes, we had to use the above-described
artificially created "stage 4 bone marrow samples" to test
the applicability of polySia-based detection of neuroblas-
toma cells in fresh samples.
Table 2: Association of polySia-NCAM and NCAM expression of untreated primary neuroblastomas with histological variables.
Variable PolySia-NCAM-positive (17) PolySia-NCAM-negative (14) P value NCAM positive (20) NCAM negative (11) P value
INPC (30*) * 0.623 * 0.165
Undifferentiated (12) 8 4 10 2
Poorly differentiated (6) 4 2 5 1
Differentiating (9) 4 5 4 5
Ganglioneuroblastoma (2) 1 1 1 1
Ganglioneuroma (1) 1 1
MEAN PI (31) 36.0 ± 17.6 19.9 ± 14.7 0.011 36.1 ± 16.6 15.3 ± 12.3 0.001
MYCN (31) 0.316 0.183
nonamplified (24) 12 12 14 10
amplified (7) 5 2 6 1
Number of patients in each group is shown in parenthesis. P-values are measured for differences between categorical variables (polySia-NCAM or NCAM expression status). 
*An intracranial neuroblastoma was excluded from the INPC classification. Abbreviations: INPC = International Neuroblastoma Pathology Classification; PI = proliferation 
index.
Kaplan-Meier survival curve for 23 patients in the advanced disease group, including patients having LC with regional lymph node involvement (4 patients) and ati ts with distant metastases (19 patients), stratified by polySia-NCAM xpression (A), NCAM expre sion (B), and MYCN amplification status (C)Figure 2
Kaplan-Meier survival curve for 23 patients in the advanced disease group, including patients having LC with 
regional lymph node involvement (4 patients) and patients with distant metastases (19 patients), stratified by 
polySia-NCAM expression (A), NCAM expression (B), and MYCN amplification status (C). The solid line repre-
sents polySia-NCAM-positive patients (16 patients), and the broken line represents polySia-NCAM-negative patients (7 
patients).Page 5 of 8
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PolySia-NCAM expression was proved to associate with
clinical stage: patients with polySia-NCAM-expressing pri-
mary neuroblastomas were shown to have an advanced
disease at diagnosis (P = 0.047). Most interestingly, posi-
tive polySia-NCAM expression is a strong prognostic fac-
tor for favorable overall survival (P = 0.0004) in advanced
disease, especially when the MYCN copy number is not
amplified. Furthermore, the vast majority (9 out of 11) of
bone marrow disseminated primary neuroblastomas had
polySia-NCAM on their cell surfaces. Because neither
polySia-NCAM nor NCAM expression associated with
MYCN amplification (Table 2), which is a common fea-
ture in metastatic neuroblastoma, it appears that polySia-
NCAM may be an independent marker for metastatic
activity in neuroblastoma, like in rhabdomyosarcoma,
NSCLC and SCLC [16,18,20]. In addition, the presence of
polySia-NCAM on cell surfaces was shown to associate
with increased neuroblastoma SH-SY5Y cell proliferation
in an in vitro assay (results not shown) and, for the first
time, in vivo (P = 0.011). Previously, polysialylation of
NCAM has been shown to increase proliferation activity in
vitro [22]. Increased cell proliferation may favor the meta-
static activity of primary tumor cells. In general, both
polySia-NCAM and NCAM are common antigens on
untreated primary neuroblastomas, especially on imma-
ture (undifferentiated and poorly differentiated) neurob-
lastoma cells. Age, which is an important prognostic
factor [2], does not seem to associate with the expression
of these antigens. It has been suggested that immunohis-
tochemically NCAM-negative NSCLC samples showing
polySia expression, carry polySia on other molecules than
NCAM [16,19]. On the basis of our results, NCAM
appears to be the only carrier of polySia in neuroblasto-
mas. As only three out of 20 NCAM-positive neuroblasto-
mas were polySia-negative, the true independent
prognostic value of NCAM expression could not be deter-
mined.
Current prognostic evaluations are based on clinical stage,
age and MYCN amplification in neuroblastoma. These
evaluations often overestimate the number of patients in
need of chemotherapy, because the evaluation cannot
define patients with stage 1–3 tumors that are capable of
spontaneous or easily induced regression. The prognostic
and therapeutic evaluation of stage 2–4 patients with the
normal MYCN copy number is often challenging, too.
According to our results, polySia-NCAM-expressing neu-
roblastoma patients with distant metastases (13 patients)
PolySia-NCAM-positive neuroblastoma cells in a bone marrow sample were double-labeled with EndoNA2-GFP (A), and anti-Ki-67 ntibody (stained with Alexa Fluor 594) (B)F gure 3
PolySia-NCAM-positive neuroblastoma cells in a bone marrow sample were double-labeled with EndoNA2-
GFP (A), and anti-Ki-67 antibody (stained with Alexa Fluor 594) (B). C, overlay image of A and B showing proliferating 
cells in context of polySia-NCAM expression. Scale bar, 40 μm.
Flow cytometry analysis of cultured polySia-NCAM-positive SH-SY5Y cells (NB +) and normal bone m rrow cells (BM) stained with polySi -binding EndoNA2-GFP fusion proteinigure 4
Flow cytometry analysis of cultured polySia-NCAM-
positive SH-SY5Y cells (NB +) and normal bone mar-
row cells (BM) stained with polySia-binding 
EndoNA2-GFP fusion protein. Unstained SH-SY5Y cells 
(NB-) served as negative control sample.Page 6 of 8
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than polySia-NCAM-negative neuroblastoma patients
with distant metastases (6 patients, all dead). Very inter-
estingly, five out of seven dead patients in the favorable
prognostic group had polySia-NCAM-positive primary
tumors (a favorable factor) with MYCN amplification (an
unfavorable factor). In other words, MYCN amplification
seems to counteract the positive prognostic value of poly-
Sia-NCAM in advanced disease group. Even though cur-
rent intensive multimodality treatment protocols may
improve the overall survival of high-risk patients, it is
unlikely that a difference in treatment protocols explains
our result. In summary, patients with polySia-NCAM-neg-
ative a.) local neuroblastoma with involvement of
regional lymph nodes (equal to INSS stage 2B-3 tumors),
or b.) neuroblastoma with distant metastases (equal to
INSS stage 4 tumors) have an unfavorable prognosis
despite MYCN amplification status, whereas patients with
polySia-NCAM-positive neuroblastomas (similar to INSS
stage 2B-4 tumors) have a more favorable prognosis, espe-
cially when the MYCN copy number is normal. In vitro
studies have shown that polySia increases the motility of
SCLC cells, and allows the cancer cells to detach from the
primary tumor, thus causing the formation of metastatic
foci [21]. In conclusion, polySia-NCAM is considered to
be a neural stem cell marker [29], and widely spread poly-
Sia-NCAM neuroblastoma cells (of neural crest origin)
may be neural stem cell-like cells obviously harboring
other than proliferative and mitotic stem cell characteris-
tics, such as differentiation, which improves prognosis.
Bone marrow is the most important secondary organ for
the detection of circulating neuroblastoma cells. Our
results show that 9 out of 11 (82%) patients with bone
marrow metastases at diagnosis had primary tumors
expressing polySia-NCAM. We also detected polySia-
NCAM-expressing neuroblastic cells in two paraffin-
embedded bone marrow samples. Interestingly, these
tumor cells had originated from a polySia-NCAM-positive
primary neuroblastoma. Previously, bone marrow metas-
tases in advanced stages of neuroblastoma were shown to
be NCAM-positive, but the polysialylation of NCAM mol-
ecules was not determined [30]. PolySia-NCAM-express-
ing tumor cells in bone marrow grew in clusters, which is
in accordance with previous in vitro results indicating that
polySia-NCAM-expressing SH-SY5Y neuroblastic tumor
cells never grow without contact with each other, even at
low densities [23]. PolySia-NCAM-positive tumor cells in
bone marrow rarely stained with anti-Ki-67 antibody. The
low proliferation activity of polySia-NCAM-positive
tumor cells in bone marrow might explain, to some
extent, the relative resistance of bone marrow metastases
to conventional chemotherapy. Very recently, it was pre-
sented that the transcript level of one of the two key
enzymes responsible for polySia synthesis, sialyltrans-
ferase STX, is a highly prognostic outcome factor for neu-
roblastoma, if measured from bone marrow after
cytotoxic treatments [19]. In that study, concomitant
MYCN amplification may explain unfavorable prognosis
in polySia-NCAM positive patients. However, if polySia-
NCAM-positive neuroblastoma cells in bone marrow
need to be treated or detected, the intensity and specificity
of our recently developed polySia-detecting fusion pro-
tein [28] allows it to be used in the detection of metastatic
disease in fresh bone marrow samples by flow cytometry,
in addition to immunohistochemical identification of
minimal residual disease in biopsies or smears. In sum-
mary, polySia-NCAM expression may favor neuroblast-
oma cell dissemination into bone marrow.
Conclusion
A subpopulation of cells in untreated primary neuroblas-
tomas contains adhesive characteristics, namely polySia-
NCAM phenotype, which associates with proliferation
activity and clinical stage. Moreover, polySia-NCAM
appears to be a pathogenetically relevant marker predict-
ing outcome, especially in advanced stage neuroblastoma,
which to date has remained a therapeutical challenge. The
specific and sensitive detection of polySia-NCAM-express-
ing primary and metastatic tumor cells may allow the
development of new immunodiagnostic and immuno-
therapeutical approaches. A better immunohistochemical
prediction of neuroblastoma behavior at diagnosis may
help to avoid treatment failure in high-risk patients. Due
to the limited number of patients, the presented results
have to be interpreted with caution. Therefore, a larger
study is warranted.
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